The Placebo Response: A Hidden Risk to COVID-19 Trials” – First Opinion written by Tools4Patient authors published in STAT News

October 20, 2020

STAT News published “The Placebo Response: A Hidden Risk to COVID-19 Trials” written by Tools4Patient authors on October 13, 2020. The article, authored by Erica Smith PhD, VP of Business Development and Dominique Demolle PhD, CEO, was published in STAT’s First Opinion column. The article asserts that the success of the abundant drug development program for COVID-19 therapies

Read More

Tools4Patient expands into new office space

September 24, 2020

The Tools4Patient team has moved our offices to a new building located in the same scientific campus in Louvain-La-Neuve, Belgium in early September, 2020. The rapid expansion of collaborations with innovative biopharma companies has led to 30% growth of our team – particularly in scientific and operational support areas – over the last year.

Read More

Tools4Patient Introduces unik-me Platform for Administration of Psychological Questionnaires in Clinical Trials

June 16, 2020

Tools4Patient (T4P) introduces unik-me, our proprietary platform to administer psychological questionnaires to patients in clinical trials.

Read More

Tools4Patient launches COV-IQ to evaluate the impact of the COVID-19 pandemic on patients in ongoing clinical trials

May 1, 2020

Tools4Patient launches COV-IQ, a new platform aiming to evaluate the impact of COVID-19 on clinical trial patients. COV-IQ aims to quantify the effect of emotional stress, change in trial conduct and changes in social structure on each trial subject.

Read More

“Modeling of Peripheral Neuropathic Pain and Osteoarthritis Placebo Response” presented at the International Society for CNS Clinical Trials and Methodology

February 21, 2020

Dr. Dominique Demolle, CEO of Tools4Patient, recently presented data at the 16th Annual Scientific Meeting of the International Society for CNS Clinical Trials and Methodology in Washington, DC. The presentation, entitled ““Modeling of Peripheral Neuropathic Pain and Osteoarthritis Placebo Response: Working Towards a Unique Model of the Placebo Response in Chronic Pain?” was authored by Tools4Patient scientist Dr. Samuel

Read More

Tools4Patient Selected as Finalist in 2019 Clinical Trials Innovations Challenge

September 16, 2019

Tools4Patient’s Placebell©™ technology has been selected as a finalist in the 2019 Clinical Trials Innovation Challenge sponsored by IQVIA, Lundbeck, and LEO Innovation Lab.

Read More

“Sensory Profiles and stratification of neuropathic pain patients based on the neuropathic pain symptom inventory (NPSI)” presented at the 2019 European Pain Federation EFIC Conference.

September 9, 2019

This study aimed to identify specific sensory phenotypes of peripheral neuropathic pain patients that could predict treatment response based on pain symptoms assessed by the Neuropathic Pain Symptom Inventory (NPSI).

Read More

Tools4Patient Raises Series B Financing for Commercial Expansion of Clinical Development Solutions

May 16, 2019

Placebell©™ technology designed to limit the negative impact of the placebo effect in clinical trials.

Read More

Opportunities Available for Collaboration

September 18, 2018

While drug developers have been struggling with the placebo response for decades, Placebell©™ is the first commercially available technology that enables scientists to control for the placebo response in clinical studies. Tools4Patient (T4P) launched Placebell©™ in late 2017,

Read More

Tools4Patient Strengthens Group’s Expertise with North American Business Development Team

May 22, 2018

The commercial launch of Placebell©™ for peripheral neuropathic pain in October 2017 has increased interest from biopharma industry stakeholders in T4P’s low-risk validated technology.

Read More